Short-Term Effectiveness, Safety, and Potential Predictors of Response of Secukinumab in Patients with Severe Hidradenitis Suppurativa Refractory to Biologic Therapy: A Multicenter Observational Retrospective Study.

Autor: Fernandez-Crehuet P; Dermatology Department, Hospital Reina Sofía de Córdoba and IMIBIC, Córdoba, Spain. pablo@crehuetdermatologos.com., Haselgruber S; Hospital Universitario Virgen de las Nieves, IBS Granada, Granada, Spain.; Hidradenitis Suppurativa Clinic, Granada, Spain., Padial-Gomez A; Dermatology Department, Hospital Universitario de Jerez de la Frontera, Jerez de la Frontera, Spain., Vasquez-Chinchay F; Dermatology Department, Hospital Universitario Virgen de Valme, Seville, Spain., Fernandez-Ballesteros MD; Dermatology Department, Hospital Universitario Regional de Málaga, Málaga, Spain., López-Riquelme I; Dermatology Department, Hospital Universitario Regional de Málaga, Málaga, Spain., Jimenez-Gallo D; Dermatology Department, Hospital Universitario Puerta del Mar, Cádiz, Spain., Segura-Palacios JM; Dermatology Department, Hospital Costa del Sol, Marbella, Spain., Contreras-Steyls M; Dermatology Department, Hospital Universitario Virgen de la Victoria, Málaga, Spain., Osorio-Gómez GF; Dermatology Department, Hospital Universitario Virgen del Rocio, Seville, Spain., Hernández-Rodríguez JC; Dermatology Department, Hospital Universitario Virgen del Rocio, Seville, Spain., Sanchez-Diaz M; Hospital Universitario Virgen de las Nieves, IBS Granada, Granada, Spain.; Hidradenitis Suppurativa Clinic, Granada, Spain., Cuenca-Barrales C; Hospital Universitario Virgen de las Nieves, IBS Granada, Granada, Spain.; Hidradenitis Suppurativa Clinic, Granada, Spain., Arias-Santiago S; Hospital Universitario Virgen de las Nieves, IBS Granada, Granada, Spain.; Hidradenitis Suppurativa Clinic, Granada, Spain., Molina-Leyva A; Hospital Universitario Virgen de las Nieves, IBS Granada, Granada, Spain.; Hidradenitis Suppurativa Clinic, Granada, Spain.; European Hidradenitis Suppurativa Foundation, Dessau-Roßlau, Germany.
Jazyk: angličtina
Zdroj: Dermatology and therapy [Dermatol Ther (Heidelb)] 2023 Apr; Vol. 13 (4), pp. 1029-1038. Date of Electronic Publication: 2023 Mar 09.
DOI: 10.1007/s13555-023-00906-2
Abstrakt: Introduction: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease. Biologic drugs have a key role in the long-term anti-inflammatory treatment of moderate to severe patients due to their immunomodulatory properties. The aim of this study is to evaluate the effectiveness and safety of secukinumab in patients with moderate to severe HS after 16 weeks of treatment, and to explore potential predictors of clinical response to the drug.
Methods: Multicenter observational retrospective study. Patients treated with secukinumab 300 mg every 2 or 4 weeks who had completed at least 16 weeks of follow-up from nine hospitals based in southern Spain (Andalusia) were included in this study. Treatment effectiveness was assessed using the Hidradenitis Suppurativa Clinical Response (HiSCR). Information about adverse events was collected, the therapeutic burden of the patients was calculated as the summation of systemic medical treatments and surgical interventions (excluding incision and drainage) experienced until the start of secukinumab treatment.
Results: Forty-seven patients with severe HS were included for analysis. At week 16, 48.9% (23/47) of patients achieved HiSCR. Adverse events were present in 6.4% (3/47) of the patients. The multivariate analysis showed that female sex and, to a lesser extent, lower body mass index (BMI) and a lower therapeutic burden were potentially associated with a higher probability of HiSCR achievement.
Conclusions: Favorable short-term effectiveness and safety of secukinumab in the treatment of severe HS patients were observed. Female sex, lower BMI and a lower therapeutic burden may be associated with a higher probability of achieving HiSCR.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje